In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalized Medicine

Set Alert for Personalized Medicine

Going Back To The Future To Treat Diabetes

Applied Therapeutics has a business model that defies the conventional wisdom about start-up success: reviving science abandoned by big pharma; financing from a narrow group of investors, dependent on the goodwill of a single academic institution; all in pursuit of a small molecule solution to one of the biggest, diversely complex and cost-defying challenges in chronic disease – the complications of diabetes. 

C-Suite Speaks Innovation Research and Development Strategies

One For All Not All For One With Personalized Therapies

Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect. 

Personalized Medicine Research and Development Strategies Research & Development

Illumina CSO Bentley Paints A Vision For The Future Of Precision Medicine

Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.

C-Suite Speaks Leadership Personalized Medicine

In Vivo’s Quick Guide To Gene Therapy

Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.

Gene Therapy Innovation Research and Development Strategies

More on Personalized Medicine from Scrip, Pink Sheet & Medtech Insight.

US FDA’s New ‘N of 1’ Guidance Essentially A Down Payment On Critical Advice

Draft guidance will help sponsor-investigators working on individualized gene therapies. The focus on basic administrative and procedural aspects of interaction with the FDA leaves many policy and commercialization questions about how these personalized investigational products should be studied unanswered.

Guidance Documents Gene Therapy

QUOTED. 16 December 2020. Komathi Stem.

Telehealth and data from devices such as continuous glucose monitors will play an increasingly important role in helping clinicians spot disease early, Glooko Chief Operating Officer Komathi Stem said during a recent panel discussion on metabesity.

Quoted Digital Health

QUOTED. 7 December. Tomas Landh.

An expert panel recently discussed the complex issues surrounding metabesity. See what panelist Tomas Landh, vice president of innovation sourcing, Novo Nordisk said about it here.      

Quoted Digital Health

Conquering Metabesity: Expert Panel Discusses Roadmap To Find Solutions

Metabesity is a complex issue that will require a multi-disciplinary approach, concerted effort and clear regulatory pathway to achieve solutions.

Digital Health Innovation

ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s

The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.

Neurology Research and Development Strategies

Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.

Financing Cancer
See All
UsernamePublicRestriction

Register